Webcast Alert: BioSante Pharmaceuticals, Inc. Presentation at Informed Investors Biotechnology/Healthcare Virtual Stocks Forum to be Webcast on Tuesday, July 27, 2004, 9:30 am ET

Jul 23, 2004, 01:00 ET from Biosante Pharmaceuticals, Inc.

    LINCOLNSHIRE, Ill., July 23 /PRNewswire/ -- BioSante Pharmaceuticals, Inc.
 (Amex:   BPA) will present at the following forum:
     What:     BioSante Pharmaceuticals (Amex:   BPA) will give a presentation at
     Informed Investors Biotechnology /Healthcare Virtual Stocks Forum.
     John McCamant, Editor, The Medical Technology Stock Letter, will deliver
     the forum keynote address at 9 am.
     When:     July 27, 2004 @ 9:30 AM Eastern Time
     Where:    http://www.informedinvestors.com/IIF_Forum.asp?ForumID=85119
     How:      Live over the Internet-Simply log on to the web at the address
     Contact:   Phillip Donenberg, Chief Financial Officer,
     If you are unable to attend the live event, the forum will be available
 via webcast at http://www.informedinvestors.com/IIF_Forum.asp?ForumID=85119.
     BioSante is developing a pipeline of hormone therapy products to treat
 both men and women. BioSante's hormone therapy products are gel formulations
 for transdermal administration that deliver bioidentical estradiol and
 testosterone.  Symptoms treated with hormone therapy in men include impotence,
 diminished sex drive, muscle weakness and osteoporosis.  Symptoms in
 menopausal women include hot flashes, vaginal atrophy, decreased libido and
 osteoporosis.  The estrogen and testosterone markets in the United States
 alone account for over $2.5 billion in annual sales.
     The company also is developing its calcium phosphate nanotechnology (CAP)
 for novel vaccines, including biodefense vaccines for toxins such as anthrax
 and ricin, and drug delivery systems.  Additional information is available
 online at http://www.biosantepharma.com.
     FORUM CONTACT:  Cary Loeser, Informed Investors, +1-804-327-3407,
     Web site:  http://www.informedinvestors.com

SOURCE Biosante Pharmaceuticals, Inc.